All In Biotech

NDA 020864 · Organon LLC

Maxalt

Rizatriptan Benzoate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Oct 1, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Jun 29, 1998

Approved uses

5

Original approval plus efficacy supplements

Registered trials

14

11 Phase 3, 1 recruiting

FAERS reports

9,569

5,593 serious, 175 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 29, 2026.

MAXALT ® and MAXALT-MLT ® are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use MAXALT should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with MAXALT, the diagnosis of migraine should be reconsidered before MAXALT is administered to treat any subsequent attacks. MAXALT is not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4) ] . MAXALT is not indicated for the prevention of migraine attacks. Safety and effectiveness of MAXALT have not been established for cluster headache. MAXALT is a serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age ( 1 ) Limitations of Use : Use only after clear diagnosis of migraine has been established ( 1 ) Not indicated for the prophylactic therapy of migraine ( 1 ) Not indicated for the treatment of cluster headache ( 1 )

Mechanism: Rizatriptan binds with high affinity to human cloned 5-HT 1B/1D receptors. MAXALT presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT 1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • MAXALT · RIZATRIPTAN BENZOATE EQ 10MG BASE · TABLET, ORAL · Prescription · TE AB
  • MAXALT · RIZATRIPTAN BENZOATE EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Rizatriptan Benzoate" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,547
  • nausea1,200
  • headache1,016
  • off label use953
  • migraine934
  • product use in unapproved indication642
  • fatigue609
  • hyperhidrosis591
  • pain568
  • sedation498
  • nightmare497
  • nephrolithiasis457

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200497
2005101
2006110
2007119
2008136
2009169
2010224
2011301
2012406
2013349
2014371
2015537
2016835
2017487
2018608
2019767
2020682
2021594
2022601
2023512
2024545
2025526
2026492

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Maxalt (Rizatriptan Benzoate)

2024 spending

$1.1M

Beneficiaries

317

1,427 claims

Per beneficiary

$3,620

$40.70 per unit

View as table
YearSpending
2020$0
2021$159,447
2022$1,197,588
2023$1,329,530
2024$1,147,397

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: Organon LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.